Paper published in a journal (Scientific congresses and symposiums)
Avelumab (MSB0010718C ; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN Solid Tumor phase 1b trial : safety, clinical activity, and PD-L1 expression
Verschraegen, C.; Chen, F.L.; Spigel, D.R.et al.
2016 • In Journal of Clinical Oncology, 34, p. 9036
Avelumab (MSB0010718C ; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN Solid Tumor phase 1b trial : safety, clinical activity, and PD-L1 expression
Publication date :
2016
Event name :
2016 ASCO Annual Meeting
Event place :
Chicago, United States
Event date :
June 3-7, 2016
Audience :
International
Journal title :
Journal of Clinical Oncology
ISSN :
0732-183X
eISSN :
1527-7755
Publisher :
American Society of Clinical Oncology, Alexandria, United States - Virginia
